Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the Veterans Health Administration
Authors' conclusion
We found no clinically meaningful differences in the effectiveness or safety of rituximab-pvvr compared with originator rituximab among incident users with RA.
Study context
- Population
- Veterans aged ≥18 years receiving originator rituximab or rituximab-pvvr for RA, Veterans Health Administration (VHA), 1 March 2020 to 31 August 20231,074 incident users
- Participants
- 1,717 veterans
- Exposure
- Rituximab-pvvr vs originator rituximab
- Outcome
- Effectiveness outcomes (e.g. prednisone use) and safety outcomes (e.g. infection)
Methodological detailsentropy-balanced subgroups of incident users, regression analyses
- Entropy-balanced subgroups of incident users
- Regression analyses
Main finding
Effectiveness: discontinued prednisone use
Risk difference (RD)
0.05
95% CI −0.04-0.14
Between Originator rituximab and Rituximab-pvvr
RD 0.05 (95% CI −0.04-0.14)
As reported in the abstract
Observational data: associations, not effects.
Safety
| Outcome | RD (95% CI) | |
|---|---|---|
| Infection-related hospitalisations or ED visits | −0.02 (−0.08-0.05) | |
| −0.1−0.0500.050.1Difference (linear scale) |
- Infection-related hospitalisations or ED visits: among 1074 incident users
Original publication
Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the Veterans Health Administration. Rheumatology (Oxford). Published 7 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →